PL1853285T3 - Sposób leczenia zapalenia związanego ze złogami amyloidowymi i zapalenia mózgu z udziałem aktywowanych komórek mikrogleju - Google Patents

Sposób leczenia zapalenia związanego ze złogami amyloidowymi i zapalenia mózgu z udziałem aktywowanych komórek mikrogleju

Info

Publication number
PL1853285T3
PL1853285T3 PL06734085T PL06734085T PL1853285T3 PL 1853285 T3 PL1853285 T3 PL 1853285T3 PL 06734085 T PL06734085 T PL 06734085T PL 06734085 T PL06734085 T PL 06734085T PL 1853285 T3 PL1853285 T3 PL 1853285T3
Authority
PL
Poland
Prior art keywords
amyloid deposits
activated microglia
involving activated
brain
inflammation associated
Prior art date
Application number
PL06734085T
Other languages
English (en)
Inventor
Beka Solomon
Orna Goren
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of PL1853285T3 publication Critical patent/PL1853285T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL06734085T 2005-02-01 2006-01-31 Sposób leczenia zapalenia związanego ze złogami amyloidowymi i zapalenia mózgu z udziałem aktywowanych komórek mikrogleju PL1853285T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64838305P 2005-02-01 2005-02-01
EP06734085A EP1853285B1 (en) 2005-02-01 2006-01-31 Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
PCT/US2006/003291 WO2006083795A1 (en) 2005-02-01 2006-01-31 Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia

Publications (1)

Publication Number Publication Date
PL1853285T3 true PL1853285T3 (pl) 2011-08-31

Family

ID=36589064

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06734085T PL1853285T3 (pl) 2005-02-01 2006-01-31 Sposób leczenia zapalenia związanego ze złogami amyloidowymi i zapalenia mózgu z udziałem aktywowanych komórek mikrogleju

Country Status (14)

Country Link
US (3) US7867487B2 (pl)
EP (1) EP1853285B1 (pl)
JP (1) JP5096169B2 (pl)
CN (1) CN101166536B (pl)
AT (1) ATE501723T1 (pl)
CY (1) CY1111455T1 (pl)
DE (1) DE602006020697D1 (pl)
DK (1) DK1853285T3 (pl)
ES (1) ES2363203T3 (pl)
HK (1) HK1110790A1 (pl)
PL (1) PL1853285T3 (pl)
PT (1) PT1853285E (pl)
SI (1) SI1853285T1 (pl)
WO (1) WO2006083795A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553567A (zh) * 2006-07-21 2009-10-07 台拉维夫大学拉莫特 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法
EP2303315A1 (en) 2008-05-22 2011-04-06 Ramot at Tel Aviv University Ltd. Method for treating disease characterized by plaque
KR20110091778A (ko) * 2008-11-24 2011-08-12 라모트 앳 텔-아비브 유니버시티 리미티드 사상 박테리오파지를 이용하는 파킨슨병의 치료방법
JP2014509514A (ja) * 2011-03-11 2014-04-21 ラモット アット テルアヴィブ ユニヴァーシティ リミテッド 神経変性タウオパシーを治療するための方法
WO2013016644A1 (en) 2011-07-27 2013-01-31 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
WO2013022717A1 (en) * 2011-08-05 2013-02-14 Neurophage Pharmaceuticals, Inc. Pure filamentous bacteriophage and methods of producing same
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
WO2013138716A1 (en) * 2012-03-15 2013-09-19 Ramot At Tel-Aviv University Ltd. The filamentous bacteriophage as an angiogenesis modulator
US9655933B2 (en) 2012-03-15 2017-05-23 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage as an angiogenesis modulator
LT2906235T (lt) * 2012-10-02 2017-10-25 Proclara Biosciences, Inc. Bakteriofago sulietų baltymų p3, kaip amiloido rišamųjų agentų, naudojimas
CN105473153A (zh) * 2013-05-28 2016-04-06 神经噬菌体制药股份有限公司 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽
ES2910017T3 (es) 2014-12-03 2022-05-11 Proclara Biosciences Inc Polipéptidos que comprenden una secuencia de aminoácidos modificada de g3p de bacteriófago que carece de una señal de glicosilación

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60044057D1 (de) * 1999-09-03 2010-05-06 Univ Ramot Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
AU2003205623A1 (en) 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates

Also Published As

Publication number Publication date
HK1110790A1 (en) 2008-07-25
US20110142803A1 (en) 2011-06-16
DK1853285T3 (da) 2011-06-27
WO2006083795A1 (en) 2006-08-10
CY1111455T1 (el) 2015-08-05
US8361458B2 (en) 2013-01-29
CN101166536B (zh) 2012-06-27
US20130177533A1 (en) 2013-07-11
JP5096169B2 (ja) 2012-12-12
ES2363203T3 (es) 2011-07-26
PT1853285E (pt) 2011-06-06
DE602006020697D1 (de) 2011-04-28
US7867487B2 (en) 2011-01-11
EP1853285B1 (en) 2011-03-16
WO2006083795A8 (en) 2007-03-15
EP1853285A2 (en) 2007-11-14
JP2008528688A (ja) 2008-07-31
SI1853285T1 (sl) 2011-07-29
US20090180991A1 (en) 2009-07-16
ATE501723T1 (de) 2011-04-15
CN101166536A (zh) 2008-04-23

Similar Documents

Publication Publication Date Title
HK1110790A1 (en) Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
WO2007084181A3 (en) Bispecific single chain fv antibody molecules and methods of use thereof
WO2006125229A8 (en) Use of tnf inhibitor for treatment of erosive polyarthritis
MX2008012023A (es) Metodos para prevenir y tratar enfermedades amiloidogenicas.
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
EA015654B9 (ru) Антитела против бета-амилоидного пептида
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
WO2007115045A3 (en) Diagnostics and treatments for tumors
TW200728466A (en) Antibody molecules having specificity for human IL-6
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
WO2006057997A3 (en) Plasmin-inhibitory therapies
GB2475660A (en) Methods and kits for treating cluster headache disorders
MX2009013840A (es) Combinaciones de agentes que disminuyen sap y anticuerpos.
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
TW200507840A (en) Method of treating multiple myeloma
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
WO2005099755A3 (en) Methods of treating autoimmune and inflammatory diseases
WO2006122035A3 (en) Method for treating central pain syndrome or for inducing centrally generated pain in an animal model
WO2008033368A3 (en) Boroproline compound and cytokine combination therapy
WO2007058957A3 (en) Boroproline compound and cytokine combination therapy